Barring a last-minute reversal, 2018 will likely end as a down year for the biotech industry, at least in terms of stock performance.
After yesterday’s big plunge in the stock market, and today with the Dow Jones Industrial Average dropping more than 500 points after opening – but mostly recovering (so far) – volatility appears to be the key word to describe the stock market
Biotech investing is a volatile business as 2018 has seen a little-known hedge fund with a focus on biotech and the life sciences beat out a couple of heavy hitters, David Einhorn and Bill Ackman.
Although the stock market seems to be moving up at the beginning of this year, the U.S. equities market appears more mixed, with healthcare stocks in particular appearing more volatile.
Todd Campbell, writing for The Motley Fool, notes four biopharma stocks that topped out in the S&P 500 in 2017.